In my opinion, Abivax is worth much more than its current share price of around €136. The market still seems to value the company as if there is a lot of uncertainty, but I believe much of that uncertainty has now been reduced.Read more

In my opinion, Iovance is one of those biotech companies where the market is still focused on what went wrong in the past instead of what could happen over the next few years. After a disappointing commercial launch in 2025, many investors lost confidence and the share price fell sharply.Read more